Trial Profile
Association of natalizumab on work ability in relapsing-remitting multiple sclerosis patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Jul 2021
Price :
$35
*
At a glance
- Drugs Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms WANT
- 01 Jul 2021 Results published in the Neurological Sciences
- 30 Oct 2018 New trial record
- 12 Oct 2018 Primary end point (Change in Work Productivity and Activity Impairment Questionnaire for MS (WPAI:MS)) has been met.